1887

Abstract

Lumpy skin disease virus (LSDV), a capripoxvirus with a host range limited to ruminants, was evaluated as a replication-deficient vaccine vector for use in non-ruminant hosts. By using the rabies virus glycoprotein (RG) as a model antigen, it was demonstrated that recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG in both permissive (ruminant) and non-permissive (non-ruminant) cells. The recombinant LSDV, however, replicated to maturity only in permissive but not in non-permissive cells. Recombinant LSDV-RG was assessed for its ability to generate immunity against RG in non-ruminant hosts (rabbits and mice). Rabbits inoculated with rLSDV-RG produced rabies virus (RV) neutralizing antibodies at levels twofold higher than those reported by the WHO to be protective. BALB/c mice immunized with rLSDV-RG elicited levels of RV-specific cellular immunity (T-cell proliferation) comparable with those of mice immunized with a commercial inactivated rabies vaccine (Verorab; Pasteur Merieux). Most importantly, mice immunized with rLSDV-RG were protected from an aggressive intracranial rabies virus challenge.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19116-0
2003-08-01
2019-12-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/8/vir841985.html?itemId=/content/journal/jgv/10.1099/vir.0.19116-0&mimeType=html&fmt=ahah

References

  1. Alexander, R. A., Plowright, W. & Haig, D. A. ( 1957; ). Cytopathic agents associated with LSD of cattle. Bull Epizoot Dis Africa 5, 489–492.
    [Google Scholar]
  2. Allen, T., Vogel, T., Fuller, D. & 11 other authors ( 2000; ). Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164, 4968–4978.[CrossRef]
    [Google Scholar]
  3. Amara, R., Villinger, F., Staprans, S. & 10 other authors ( 2002; ). Different patterns of immune responses but similar control of a simian–human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 76, 7625–7631.[CrossRef]
    [Google Scholar]
  4. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. ( 1998; ). The complete genomic sequence of the MVA strain: comparison with other orthopoxviruses. Virology 244, 365–396.[CrossRef]
    [Google Scholar]
  5. Aspden, K. ( 2002; ). A study of the host-restricted lumpy skin disease virus as a vaccine vector using rabies virus as a model. PhD Thesis, University of Cape Town, South Africa.
  6. Aspden, K., van Dijk, A. A., Bingham, J., Cox, D., Passmore, J. & Williamson, A.-L. ( 2002; ). Immunogenicity of a recombinant lumpy skin disease virus (Neethling vaccine strain) expressing the rabies virus glycoprotein in cattle. Vaccine 20, 2693–2701.[CrossRef]
    [Google Scholar]
  7. Barouche, D. H., Santra, S., Kuroda, M. J. & 13 other authors ( 2001; ). Reduction of simian–human immunodeficiency virus 89.6P viraemia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 75, 5151–5158.[CrossRef]
    [Google Scholar]
  8. Baxby, D. & Paoletti, E. ( 1992; ). Potential use of non-replicating vectors as recombinant vaccines. Vaccine 10, 8–9.[CrossRef]
    [Google Scholar]
  9. Belshe, R. B., Stevens, C., Gorse, G. J. & 20 other authors ( 2001; ). Safety and immunogenicity of a canarypox-vectored HIV-1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 183, 1343–1352.[CrossRef]
    [Google Scholar]
  10. Bender, B. S., Rowe, C. A., Taylor, F., Wyatt, L. S., Moss, B. & Small, P. A. ( 1996; ). Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 70, 6418–6424.
    [Google Scholar]
  11. Boyle, D. B. & Coupar, B. E. H. ( 1988; ). A dominant selectable marker for the construction of recombinant poxviruses. Gene 65, 123–128.[CrossRef]
    [Google Scholar]
  12. Cadoz, M., Strady, A., Meignier, B., Taylor, J., Tartaglia, J., Paoletti, E. & Plotkin, S. ( 1992; ). Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339, 1429–1449.[CrossRef]
    [Google Scholar]
  13. Carroll, M. W., Overwijk, W., Surman, D., Tsung, K., Moss, B. & Restifo, M. ( 1998; ). Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, IL-12, and a model tumour antigen. J Natl Cancer Inst 90, 1881–1887.[CrossRef]
    [Google Scholar]
  14. Cliquet, F., Aubert, M. & Sagne, L. ( 1998; ). Development of F1 antibody virus neutralization test (FAVN) for the quantitation of rabies virus neutralizing antibodies. J Immunol Methods 212, 79–89.[CrossRef]
    [Google Scholar]
  15. Cohen, A., Cox, D., van Dijk, A. A., Korber, A., Dumbell, K. R. & Williamson, A.-L. ( 1997; ). Lumpy skin disease virus as a vaccine vector for rift valley fever virus and bovine ephemeral fever virus. In Proceedings of the 4th Congress of the European Society for Veterinary Virology, Edinburgh, UK, 24–17 August, pp. 230–231.
  16. Dean, D. J., Abelseth, M. K. & Atanasiu, P. ( 1996; ). The fluorescent antibody test. In Laboratory Techniques in Rabies, 4th edn, pp. 88–95. Edited by F.-X. Meslin, M. M. Kaplan & H. Koprowski. Geneva: World Health Organization.
  17. Dutta, J. K., Pradhan, S. C. & Dutta, T. K. ( 1992; ). Rabies antibody titres in vacinees: protection, failure and prospects. Int J Clin Pharmacol Ther Toxicol 30, 107–112.
    [Google Scholar]
  18. Gupta, K., Hudgens, M., Corey, L. & 14 other authors ( 2002; ). Safety and immunogenicity of a high-titred canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A. J Acquir Immune Defic Syndr 29, 254–261.[CrossRef]
    [Google Scholar]
  19. Hirsch, V. M., Fuerst, T. R., Sutter, G. & 9 other authors ( 1996; ). Patterns of viral replication correlate with outcome in SIV-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70, 3741–3752.
    [Google Scholar]
  20. Horig, H., Lee, D., Conkright, W. & 10 other authors ( 2000; ). Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49, 504–514.[CrossRef]
    [Google Scholar]
  21. MacGregor, G. R. & Caskey, C. T. ( 1989; ). Construction of plasmids that express E. coli β-galactosidase in mammalian cells. Nucleic Acids Res 7, 2365.
    [Google Scholar]
  22. MacGregor, G. R., Nolan, G. P., Fiering, S., Roederer, H. & Herzenberg, L. A. ( 1991; ). Use of E. coli lacZ (β-galactosidase) as a reporter gene. Methods Mol Biol 7, 217–235.
  23. Mayr, A. & Danner, K. ( 1978; ). Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41, 225–234.
    [Google Scholar]
  24. Men, R., Wyatt, L., Tokimatsu, I., Arakaki, S., Shameem, G., Elkins, R., Chanock, R., Moss, B. & Lai, C. ( 2000; ). Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2-virus challenge. Vaccine 18, 3113–3122.[CrossRef]
    [Google Scholar]
  25. Merchlinsky, M. & Moss, B. ( 1992; ). Introduction of foreign DNA into the VV genome by in vitro ligation: recombinant-independent selectable cloning vectors. Virology 190, 522–526.[CrossRef]
    [Google Scholar]
  26. Meyer, H., Sutter, G. & Mayr, A. ( 1991; ). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031–1038.[CrossRef]
    [Google Scholar]
  27. Mifune, K., Takeuchi, E., Napiorkowski, P. A., Yamada, A. & Sakamoto, K. ( 1981; ). Essential role of T-cells in the post-exposure prophylaxis of rabies in mice. Microbiol Immunol 25, 895–904.[CrossRef]
    [Google Scholar]
  28. Moss, B. ( 1996; ). Genetically engineered poxviruses for recombinant gene expression, variation, and safety. Proc Natl Acad Sci U S A 93, 11341–11348.[CrossRef]
    [Google Scholar]
  29. Moss, B. ( 2001; ). Poxviridae: the viruses and and their replication. In Virology, 4th edn, pp. 2849–2883. Edited by D. M. Knipe & P. M. Howley. Philidelphia: Lippincott Williams and Wilkins.
  30. Moss, B., Carroll, M. W., Wyatt, L. S. & 11 other authors ( 1996; ). Host range restricted non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397, 7–13.
    [Google Scholar]
  31. Paoletti, E. ( 1996; ). Applications of poxvirus vectors to vaccination: an update. Proc Natl Acad Sci U S A 93, 11349–11353.[CrossRef]
    [Google Scholar]
  32. Perkus, M., Piccini, A., Lipinskas, B. & Paoletti, E. ( 1985; ). Recombinant vaccinia virus: immunization against multiple pathogens. Science 229, 981–984.[CrossRef]
    [Google Scholar]
  33. Prozesky, L. & Barnard, B. J. H. ( 1982; ). A study of the pathology of lumpy skin disease in cattle. Onderstepoort J Vet Res 49, 167–175.
    [Google Scholar]
  34. Redfield, R. R., Wright, D. C., James, W. D., Jones, T. S., Brown, C. & Burke, D. C. ( 1987; ). Disseminated vaccinia in military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316, 673–676.[CrossRef]
    [Google Scholar]
  35. Rodriguez, D., Rodriquez, J. R., Rodriguez, J. F., Trauber, D. & Esteban, M. ( 1989; ). Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci U S A 86, 1287–1291.[CrossRef]
    [Google Scholar]
  36. Romero, C. H., Barret, T., Evans, S. A., Kitching, R. P., Gershan, P. D., Bostock, C. & Black, D. N. ( 1993; ). Single capripox recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease. Vaccine 11, 737–742.[CrossRef]
    [Google Scholar]
  37. Romero, C. H., Barrett, T., Chamberlain, R. W., Kitching, P., Flemming, M. & Black, D. N. ( 1994a; ). Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease virus. Virology 204, 425–429.[CrossRef]
    [Google Scholar]
  38. Romero, C. H., Barrett, T., Kitching, R. P., Carn, V. M. & Black, D. N. ( 1994b; ). Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus. Vet Rec 135, 154–154.[CrossRef]
    [Google Scholar]
  39. Seligmann, E. B. J. ( 1973; ). The NIH test for potency. In Laboratory Techniques in Rabies, 3rd edn, pp. 229–286. Edited by M. M. Kapman & H. Koprowski. Geneva: World Health Organization.
  40. Smith, G. & Moss, B. ( 1983; ). Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25, 21–28.[CrossRef]
    [Google Scholar]
  41. Somogyi, P., Frazier, J. & Skinner, M. A. ( 1993; ). Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in non-permissive mammalian cells. Virology 197, 439–444.[CrossRef]
    [Google Scholar]
  42. Stannard, L. M., Marais, D., Kow, D. & Dumbell, K. ( 1998; ). Evidence for incomplete replication of penguin poxvirus in cells of mammalian origin. J Gen Virol 79, 1637–1646.
    [Google Scholar]
  43. Stittelaar, K., Kuiken, T., de Swart, R. & 8 other authors ( 2001; ). Safety of MVA in immune-suppressed macaques. Vaccine 19, 3700–3709.[CrossRef]
    [Google Scholar]
  44. Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R. & Moss, B. ( 1994; ). A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032–1040.[CrossRef]
    [Google Scholar]
  45. Taylor, J., Weinberg, R., Languet, B., Desmettre, P. & Paoletti, E. ( 1988; ). Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6, 497–503.[CrossRef]
    [Google Scholar]
  46. Taylor, J., Trimarchi, C., Weinberg, R., Languet, B., Guillemin, F., Desmettre, P. & Paoletti, E. ( 1991; ). Efficacy studies on a canarypox–rabies recombinant virus. Vaccine 9, 190–193.[CrossRef]
    [Google Scholar]
  47. Tulman, E., Afonso, C., Lu, Z., Zsak, L., Kutish, G. & Rock, D. ( 2001; ). Genome of LSDV. J Virol 75, 7122–7130.[CrossRef]
    [Google Scholar]
  48. Tulman, E. R., Afonso, C., Lu, Z. & 7 other authors ( 2002; ). The genomes of sheeppox and goatpox viruses. J Virol 76, 6054–6061.[CrossRef]
    [Google Scholar]
  49. Weiss, K. E. ( 1968; ). Lumpy skin disease virus. Virol Monogr 3, 111–130.
    [Google Scholar]
  50. Welter, J., Taylor, J., Tartaglia, J., Paoletti, E. & Stephenson, C. ( 2000; ). Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol 74, 6358–6367.[CrossRef]
    [Google Scholar]
  51. Willey, R., Byrum, R., Piatak, M. & 8 other authors ( 2003; ). Control of viremia and prevention of SHIV-induced disease in rhesus macaques immunized with recombinant VV plus inactivated SIV and HIV-1 particles. J Virol 77, 1163–1174.[CrossRef]
    [Google Scholar]
  52. WHO (World Health Organization). ( 1980; ). The Global Eradication of Smallpox. Final Report of the Global Commission for the Certification of Smallpox Eradication. History of International Public Health, no. 4. Geneva: World Health Organization.
  53. Wyatt, L. S., Shors, S. T., Murphy, B. R. & Moss, B. ( 1996; ). Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14, 1451–1458.[CrossRef]
    [Google Scholar]
  54. Wyatt, L. S., Carroll, M. W., Czerny, C. P., Merchlinsky, M., Sisler, J. R. & Moss, B. ( 1998; ). Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251, 334–342.[CrossRef]
    [Google Scholar]
  55. Xiang, Z. Q., Knowles, B. B., McCarrick, J. W. & Ertl, H. C. ( 1995; ). Immune effector mechanisms required for protection to rabies virus. Virology 214, 398–404.[CrossRef]
    [Google Scholar]
  56. Young, E., Basson, P. A. & Weiss, K. E. ( 1970; ). Experimental infection of game animals with lumpy skin disease virus (prototype strain Neethling). Onderstepoort J Vet Res 32, 79–88.
    [Google Scholar]
  57. Zavala, F., Rodrigues, M., Rodriguez, D., Rodriguez, J., Nussenzweig, R. & Esteban, M. ( 2001; ). A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8+ T cells. Virology 280, 155–159.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19116-0
Loading
/content/journal/jgv/10.1099/vir.0.19116-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error